SEC Form 4 · accession 0001615774-18-002321
Emmaus Life Sciences, Inc. · EMMA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter Unanue
Director
Period of report
Mar 29, 2018
Accepted (ET)
Apr 2, 2018 · 7:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000822370
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred StockF1,F2 | $1.875 | Mar 29, 2018 | A | 50,000 | A | — | — | Common Stock | 50,000 | 50,000 | D |
| WarrantF1,F3 | $2.34 | Mar 29, 2018 | A | 50,000 | A | — | — | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F150,000 shares of Series A Preferred Stock and Warrants to purchase 50,000 shares of Common Stock were purchased by the Reporting Person for an aggregate of $100,000 pursuant to a Subscription Agreement, dated as of March 29, 2018 (the "Subscription Agreement"), between the Issuer and the investors party thereto. The Series A Preferred Stock are convertible by the Reporting Person as of the date of the Subscription Agreement and are convertible at a conversion price of $1.875 per share.
- F2Each Share of Series A Preferred Stock is convertible, at the holder's option at any time, initially into 50,000 shares of the Issuer's Common Stock, subject to specific adjustments and limitations as set forth in the Certificate of Designation pertaining to such Series A Preferred Stock.
- F3Each Warrant entitles its holder to purchase one share of Common Stock at an exercise price of $2.34 per share, subject to adjustment, at any time commencing on March 29, 2018 and expiring on March 29, 2023 (or earlier upon redemption or liquidation).